Myriad Genetics | MYGN - Equity Capital And Reserves


Myriad Genetics reported $303.9M in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
Agilent USD 7.12B 214M Mar/2026
Becton, Dickinson and Co. USD 24.42B 283M Jun/2026
Bio-Rad Laboratories USD 7.17B 322.6M Jun/2026
Bruker USD 2.5B 46.3M Mar/2026
Danaher USD 52.58B 368M Jun/2026
Illumina USD 2.84B 162M Jun/2026
J&J USD 84.97B 3.78B Jun/2026
Mettler Toledo International USD 12.82M 54.71M Jun/2026
Myriad Genetics USD 303.9M 33.5M Jun/2026
OraSure Technologies USD 313.32M 27.5M Mar/2026
Pacific Biosciences Of California USD -33.21M 35.58M Jun/2026
Quest Diagnostics USD 7.52B 150M Jun/2026
Quidel USD 1.85B 69.1M Mar/2026
Repligen USD 2.11B 6.57M Jun/2026
Revvity USD 7.18B 67.62M Mar/2026
Standard Biotools USD 561.12M 136.83M Mar/2026
Thermo Fisher Scientific USD 51.93B 1.6B Mar/2026
Veracyte USD 1.39B 44M Jun/2026
Waters USD 15.29B 12.73B Mar/2026